Concepedia

Matthew A. Gubens

MA

Statistics

Publications

89

Citations

21K

H-Index

45

Active since

2003

Affiliations

University of California, San Francisco(Current)

Merck & Co., Inc., Rahway, NJ, USA (United States)

UCSF Helen Diller Family Comprehensive Cancer Center

Memorial Sloan Kettering Cancer Center

Dana-Farber Cancer Institute

Matthew A. Gubens is an author at University of California, San Francisco specializing in oncology, medicine, and lung cancer.

ORCID

Publications per year

2003–2025

89

Publications

89

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Edward B. Garon, Naiyer A. Rizvi, Rina Hui et al. · New England Journal of Medicine · 2015 · 6.2K citations · Full text

, , +17

Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

David S. Ettinger, Douglas E. Wood, Dara L. Aisner et al. · Journal of the National Comprehensive Cancer Network · 2022 · 1.4K citations

, , +16

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

Corey J. Langer, Shirish M. Gadgeel, Hossein Borghaei et al. · The Lancet Oncology · 2016 · 1.4K citations

, , +13

Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology

David S. Ettinger, Douglas E. Wood, Dara L. Aisner et al. · Journal of the National Comprehensive Cancer Network · 2017 · 1.3K citations

, , +17

NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021

David S. Ettinger, Douglas E. Wood, Dara L. Aisner et al. · Journal of the National Comprehensive Cancer Network · 2021 · 1K citations · Full text

, , +17

1–5 of 89